Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans - Takeaways - MDSpire

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans

  • By

  • Mehrnaz Siavoshi

  • Stephen Frochen

  • Mary Fakunle

  • Ananta Wadhwa

  • Ashley-Marie Y. Green-Lott

  • Anissa V. Bailey

  • Lorna Kwan

  • Candace Haroldsen

  • Atim Effiong

  • Brent S. Rose

  • Timothy R. Rebbeck

  • Hari S. Iyer

  • Isla P. Garraway

  • July 6, 2026

  • 0 min

Share

  • 1

    PSA screening for prostate cancer is controversial, with the USPSTF advising against routine screening for all men since 2012.

  • 2

    By 2018, guidelines shifted to recommend shared decision-making for PSA screening in men aged 55 to 69 years due to emerging evidence.

  • 3

    The study analyzed PSA screening patterns and metastatic prostate cancer incidence among veterans using data from the VA health care system.

  • 4

    Key screening factors evaluated included age at first PSA test, PSA test value, and screening interval prior to biopsy.

  • 5

    The primary outcome was prostate cancer diagnosis at first needle biopsy, categorized as metastatic, localized, or benign.

Original Source(s)

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans

  • by Mehrnaz Siavoshi, Stephen Frochen, Mary Fakunle, Ananta Wadhwa, Ashley-Marie Y. Green-Lott, Anissa V. Bailey, Lorna Kwan, Candace Haroldsen, Atim Effiong, Brent S. Rose, Timothy R. Rebbeck, Hari S. Iyer, Isla P. Garraway

  • July 6, 2026

Related Content

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

  • July 2, 2026

  • 1 min
Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing